Nath Bio-Genes (India) enterprise value

Share price at each year-end

Tap a line for its trend	Currentlast 12M	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus


252	—	—	—	—	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
76.0	76.0	88.9	77.4	38.0
139	139	123	105	105
314	—	—	—	—
62.5	62.5	33.6	28.1	67.2
₹165.27	—	—	—	—

819	819	767	715	678
16.9%	16.9%	16.0%	14.7%	15.5%
0.44×	—	—	—	—

0.64×	—	—	—	—
6.37×	—	—	—	—
6.93×	—	—	—	—
490	445	365	333	301
49.3	52.4	49.8	49.9	48.7
45.3	48.5	46.0	46.6	45.7
—	−12.6	17.6	70.3	38.4
−15.6	−15.6	9.7	61.9	35.8
—	−17.2	9.1	61.5	35.5
—	3.0	7.9	8.4	2.5

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

NATHBIOGEN₹132.38

Nath Bio-Genes (India) Limited

· FMCG & Retail

₹ CrorePeersSARVESHWAR INDOUS SUKHJITS KOHINOOR AGRITECH REGAAL BSHSL GULPOLYMcap ₹252 Cr

HighlightsEnterprise Value Multiples Per ShareAnnuals · FY-end closes

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Current/LTM TTM · last close
Market Capitalization	—	—	—	—	251.6
- Cash, Equiv & ST Investments	38.0	77.4	88.9	76.0	76.0
+ Total Debt	105.2	105.5	122.5	138.5	138.5
Enterprise Value	—	—	—	—	314.1
Net Debt (memo)	67.2	28.1	33.6	62.5	62.5
EV per Share	—	—	—	—	165.27

Total Capital	678.4	715.4	766.9	819.0	819.0
Total Debt/Total Capital	15.51	14.74	15.97	16.91	16.91
Total Debt/EV	—	—	—	—	0.44

EV/Sales	—	—	—	—	0.64
EV/EBITDA	—	—	—	—	6.37
EV/EBIT	—	—	—	—	6.93
Reference Items — Trailing FY Values
Sales	301.4	332.6	364.9	445.1	489.8
EBITDA	48.7	49.9	49.8	52.4	49.3
EBIT	45.7	46.6	46.0	48.5	45.3
Operating Cash Flow	38.4	70.3	17.6	-12.6	—
Free Cash Flow	35.8	61.9	9.7	-15.6	-15.6
FCFF (free cash flow to the firm)	35.5	61.5	9.1	-17.2	—
Capital Expenditure	2.5	8.4	7.9	3.0	—

Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.